United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
United Therapeutics Corp. (UTHR) PT Raised to $124 at Ladenburg Thalmann
February 28, 2019 8:41 AM ESTLadenburg Thalmann analyst Matthew Kaplan raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $124.00 (from $117.00) while maintaining a Neutral rating.
... MoreUnited Therapeutics (UTHR) Tops Q4 EPS by 79c, Revenues Beat
February 27, 2019 6:03 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.34, $0.79 better than the analyst estimate of $2.55. Revenue for the quarter came in at $381.4 million versus the consensus estimate of $355.83 million.
"2018 was a truly transformative year for United Therapeutics. We signed four major agreements to acquire new product... More
